Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
NCT ID: NCT02268981
Last Updated: 2015-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2014-09-30
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Oxymizer Pendant Cannula Versus Conventional Nasal Cannula During Endurance Shuttle Walk Tests in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis
NCT03411876
Effects of Supplemental Oxygen Delivered by a Portable Oxygen Concentrator Compared to a Liquid Oxygen Device in COPD
NCT03174210
Portable Oxygen Concentrator to Improve Quality of Life in Chronic Obstructive Pulmonary Disease
NCT01948544
Effects of Long-term Dry and Humidified Low-flow Oxygen Via Nasal Cannula
NCT02515786
Physiological Effects of HFNC During Exercise in Patients With Fibrosing Interstitial Lung Diseases
NCT05372926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The following 3 interventions will be performed in randomized order:
Day A: The Patient wears a conventional nasal cannula for 12 h with oxygen flow rate as prescribed during ADL
Day B: The Patient wears the Oxymizer® with prescribed oxygen flow rate for 12 h during ADL
Day C: The patient wears the Oxymizer® with a flow rate reduced by 1l/min in comparison to the prescribed oxygen flow rate, for 12h
The following week the same measurements will be repeated. The mean of the corresponding two measures will be calculated for each approach.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxymizer® compared to CNC
From 7am to 7pm oxygen saturation is measured by a pulse oximeter. One day with conventional nasal cannula, one day with Oxymizer®, one day with Oxymizer® and reduced Oxygen flow (-1l/min). The order of these days is randomized in 6 groups.
The intervention will be performed on consecutive days and twice during study period.
Oxymizer® compared to CNC
Oxygen Saturation measurement for 12 h with CNC
Oxymizer® compared to CNC
Oxygen Saturation measurement for 12 h with Oxymizer®
Oxymizer® compared to CNC
Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxymizer® compared to CNC
Oxygen Saturation measurement for 12 h with CNC
Oxymizer® compared to CNC
Oxygen Saturation measurement for 12 h with Oxymizer®
Oxymizer® compared to CNC
Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* VC \>30% and \< 70% pred.
Exclusion Criteria
* acute infection
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Schön Klinik Berchtesgadener Land
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Klaus Kenn
Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Klaus Kenn, Dr. med
Role: STUDY_CHAIR
Schoen Klinik BGL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinikum Berchtesgadener Land der Schön-Kliniken
Schönau am Königssee, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12hOXY-ILD2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.